Design, synthesis, and biological evaluation of novel trifluoromethyl indoles as potent HIV-1 NNRTIs with an improved drug resistance profile.

A novel series of trifluoromethyl indole derivatives have been designed, synthesized and evaluated for anti-HIV-1 activities in MT-2 cells. The hydrophobic constant, acute toxicity, carcinogenicity and mutagenicity were predicted. Trifluoromethyl indoles 10i and 10k showed extremely promising activities against WT HIV-1 with IC50 values at the low nanomolar level, similar to efavirenz, better than nevirapine, and also possessed higher potency towards the drug-resistant mutant strain Y181C than nevirapine. Preliminary SAR and docking studies of detailed binding mode provided some insights for discovery of more potent NNRTIs.

[1]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[2]  W. R. Dolbier,et al.  Fluorine-containing molecules : structure, reactivity, synthesis, and applications , 1988 .

[3]  I. Ojima,et al.  Biomedical Frontiers of Fluorine Chemistry , 1996 .

[4]  C. Nielsen,et al.  Multiple pathways in the synthesis of new annelated analogues of 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (emivirine). , 2003, Organic & biomolecular chemistry.

[5]  Yucheng Gu,et al.  Synthesis and anti-tumor activity of 2-amino-3-cyano-6-(1H-indol-3-yl)-4-phenylpyridine derivatives in vitro. , 2011, European journal of medicinal chemistry.

[6]  P. T. Jørgensen,et al.  Synthesis and evaluation of double-prodrugs against HIV. Conjugation of D4T with 6-benzyl-1-(ethoxymethyl)-5-isopropyluracil (MKC-442, emivirine)-type reverse transcriptase inhibitors via the SATE prodrug approach. , 2005, Journal of medicinal chemistry.

[7]  W. Karcher,et al.  Predictions for existing chemicals-a multilateral QSAR project. , 1995, SAR and QSAR in environmental research.

[8]  Koen Andries,et al.  TMC125, a Novel Next-Generation Nonnucleoside Reverse Transcriptase Inhibitor Active against Nonnucleoside Reverse Transcriptase Inhibitor-Resistant Human Immunodeficiency Virus Type 1 , 2004, Antimicrobial Agents and Chemotherapy.

[9]  Paul Watts,et al.  Synthesis of substituted indoles using continuous flow micro reactors , 2010 .

[10]  V. Soloshonok,et al.  Fluorine-containing amino acids : synthesis and properties , 1995 .

[11]  V. Soloshonok.  Enantiocontrolled synthesis of fluoro-organic compounds : stereochemical challenges and biomedical targets , 1999 .

[12]  E. Scriven,et al.  Azides: their preparation and synthetic uses , 1988 .

[13]  Marc Y. Stevens,et al.  A microwave-assisted, propylphosphonic anhydride (T3P®) mediated one-pot Fischer indole synthesis , 2011 .

[14]  W. Greenlee,et al.  5-chloro-3-(phenylsulfonyl)indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase. , 1993, Journal of medicinal chemistry.

[15]  C. Nielsen,et al.  Synthesis and evaluation of new potential HIV-1 non-nucleoside reverse transcriptase inhibitors. New analogues of MKC-442 containing Michael acceptors in the C-6 position. , 2003, Organic & biomolecular chemistry.

[16]  Jianhua Yao,et al.  SVM approach for predicting LogP , 2006, Molecular Diversity.

[17]  Jinlong Jiang,et al.  Synthesis of Monotrifluoromethyl-Substituted Saturated Cycles , 2000 .

[18]  Hong Lu,et al.  Design, synthesis, and evaluation of diarylpyridines and diarylanilines as potent non-nucleoside HIV-1 reverse transcriptase inhibitors. , 2010, Journal of medicinal chemistry.

[19]  D I Stuart,et al.  Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation non-nucleoside inhibitors. , 2001, Journal of molecular biology.

[20]  E. Novellino,et al.  New nitrogen containing substituents at the indole-2-carboxamide yield high potent and broad spectrum indolylarylsulfone HIV-1 non-nucleoside reverse transcriptase inhibitors. , 2012, Journal of medicinal chemistry.

[21]  Silvio Massa,et al.  Novel indolyl aryl sulfones active against HIV-1 carrying NNRTI resistance mutations: synthesis and SAR studies. , 2003, Journal of medicinal chemistry.

[22]  L. Jones,et al.  Synthetic chemistry-led creation of a difluorinated biaryl ether non-nucleoside reverse transcriptase inhibitor. , 2007, Organic & biomolecular chemistry.

[23]  William L Jorgensen,et al.  Computationally-guided optimization of a docking hit to yield catechol diethers as potent anti-HIV agents. , 2011, Journal of medicinal chemistry.

[24]  William L. Jorgensen,et al.  Efficient discovery of potent anti-HIV agents targeting the Tyr181Cys variant of HIV reverse transcriptase. , 2011, Journal of the American Chemical Society.

[25]  Robert A. Domaoal,et al.  Discovery of dimeric inhibitors by extension into the entrance channel of HIV-1 reverse transcriptase. , 2012, Bioorganic & medicinal chemistry letters.

[26]  E. Novellino,et al.  New arylthioindoles and related bioisosteres at the sulfur bridging group. 4. Synthesis, tubulin polymerization, cell growth inhibition, and molecular modeling studies. , 2009, Journal of medicinal chemistry.

[27]  E. Seminari,et al.  Etravirine for the treatment of HIV infection , 2008, Expert review of anti-infective therapy.

[28]  Richard A. Lerner,et al.  Proline-Catalyzed Direct Asymmetric Aldol Reactions , 2000 .

[29]  Matthew McCallum,et al.  Molecular Mechanism of Antagonism between the Y181C and E138K Mutations in HIV-1 Reverse Transcriptase , 2012, Journal of Virology.

[30]  Erik De Clercq,et al.  ANTI-HIV CHEMOTHERAPY: CURRENT STATE OF THE ART , 2004, Medicinal Chemistry Research.

[31]  M. de Béthune,et al.  Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies. , 2010, AIDS research and human retroviruses.

[32]  E. Novellino,et al.  Indolylarylsulfones bearing natural and unnatural amino acids. Discovery of potent inhibitors of HIV-1 non-nucleoside wild type and resistant mutant strains reverse transcriptase and coxsackie B4 virus. , 2009, Journal of medicinal chemistry.

[33]  Jianhua Yao,et al.  Prediction of mutagenic toxicity by combination of Recursive Partitioning and Support Vector Machines , 2007, Molecular Diversity.

[34]  K. Mahadevan,et al.  Efficient Synthesis of 2-Ethoxycarbonyl Indoles , 2009 .

[35]  E. Novellino,et al.  Indolylarylsulfones as HIV-1 non-nucleoside reverse transcriptase inhibitors: new cyclic substituents at indole-2-carboxamide. , 2011, Journal of medicinal chemistry.

[36]  Thomas Lengauer,et al.  A fast flexible docking method using an incremental construction algorithm. , 1996, Journal of molecular biology.

[37]  G. McGaughey,et al.  Design and synthesis of conformationally constrained inhibitors of non-nucleoside reverse transcriptase. , 2011, Journal of medicinal chemistry.

[38]  M. Peeters,et al.  A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. , 2008, British journal of clinical pharmacology.

[39]  Stephen H Hughes,et al.  High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations , 2008, Proceedings of the National Academy of Sciences.

[40]  D. Ramachary,et al.  Direct catalytic asymmetric synthesis of highly functionalized 2-methylchroman-2,4-diols via Barbas-list aldol reaction. , 2009, Chemistry.

[41]  Bingjie Qin,et al.  Design, synthesis, and preclinical evaluations of novel 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI) drug candidates. , 2012, Journal of medicinal chemistry.

[42]  A Panaye,et al.  CISOC-PSCT: a predictive system for carcinogenic toxicity , 2004, SAR and QSAR in environmental research.